PR Newswire·Jun 26, 2026, 9:42 AM ET

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Eleven clinical sites are now open for patient enrollment in Curis's Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib.
Curis reaffirmed its guidance to dose the initial five patients in the TakeAim CLL study by the end of July 2026, with data expected in December 2026.
Stockholders approved a reverse stock split proposal at a special meeting held on June 25, 2026, to regain compliance with Nasdaq's $1.00 bid price rule.
The reverse stock split ratio will range from 1-for-5 to 1-for-25, with the final ratio determined at the discretion of the Board of Directors.
Curis shares will continue to trade on the Nasdaq Capital Market under the ticker symbol "CRIS" following the split.
The TakeAim CLL study targets patients with chronic lymphocytic leukemia who are in partial response or partial response with lymphocytosis while actively taking zanubrutinib for at least 12 months.
Curis currently lacks sufficient cash on hand to support operations for the next 12 months from the press release date & requires substantial additional funding.
Emavusertib holds Orphan Drug Designation from the FDA for PCNSL, AML, & MDS, & from the European Commission for PCNSL.